Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: The PRIME Study

Journal of Human Hypertension

Volumn 14, Issue 8, 2000, Pages 511-518

  Marques Vidal, P ^a   Montaye, M ^b   Haas, B ^c   Bingham, A ^d   Evans, A ^e   Juhan Vague, I ^f   Ferrieres J ^a   Luc, G ^b   Amouyel, P ^b   Arveiler, D ^c   McMaster, D ^e   Ruidavets, J B ^a   Bard, J M ^b   Scarabin, P Y ^d   Ducimetiere P ^d  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c MONICA Project   (France)

^d HÔPITAL BROUSSAIS   (France)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f TIMONE HOSPITAL   (France)

Author keywords

Drug treatment; Epidemiology; Haemostasis; Lipids; Lipoproteins

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; DISEASE ASSOCIATION; HEMOSTASIS; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN;

EID: 0033844019     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001061     Document Type: Article

References (40)

1. Trends in cardiovascular disease mortality in industrialized countries since 1950
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I: Reduction in incidence of coronary heart disease
3. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial
4. Treatment of Mild Hypertension Study. Final results
5. Blood pressure, antihypertensive drugs treatment and the risks of stroke and coronary heart disease
6. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context
7. Antihypertensive drugs and lipid profiles
8. Cardiovascular risk factors in treated hypertensive - A nation-wide, cross-sectional study in Sweden
9. Antihypertensive drug treatment and fibrinolytic function
10. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree
11. Effects of antihypertensive therapy on serum lipids
12. Metabolic effects of antihypertensive drugs
13. Factor VII in an industrial population
14. Apolipoprotein A-I containing lipoproteins in coronary artery disease
15. Patterns of alcohol consumption in middle-aged men from France and Northern Ireland. The PRIME Study
16. Effect of drinking pattern on plasma lipoproteins and body weight
17. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals
18. Clustering of cardiovascular risk factors: Targeting high-risk individuals
19. The Prospective Cardiovascular Munster Study: Prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension
20. Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study
21. Hyperlipidaemia, hypertension, and coronary heart disease
22. Haemostatic variables in arterial hypertension
23. Impaired fibrinolysis and insulin resistance in patients with hypertension
24. Haemostasis balance disorders in patients with essential hypertension
25. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances
26. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden
27. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients
28. The association of antihypertensive treatment patterns and adverse lipid effects in population-based studies
29. Effects of antihypertensive agents on coronary artery disease risk factors
30. Effects of a cardioselective beta-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk
31. Effects of doxazocin and propranolol administration on lipoprotein lipases in cholesterol-fed rats
32. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride
33. Long-term effects on plasma lipids of diet and drugs to treat hypertension
34. Comparison of the effects of captopril and nicardipine on insulin sensitivity and thrombotic profile in patients with hypertension and android obesity. Captopril Insulin Sensitivity Multicenter Study Group
35. Uradipil treatment decreases plasma fibrinogen concentration in essential hypertension
36. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men
37. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1
38. Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension
39. Effects of medium-term antihypertensive therapy on haemostatic parameters in patients with essential hypertension
40. Assessing hypertension control in the community: The need for follow-up measurements to ensure clinical relevance